GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » EV-to-Revenue

InnoCan Pharma (XCNQ:INNO) EV-to-Revenue : 4.60 (As of May. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, InnoCan Pharma's enterprise value is C$84.54 Mil. InnoCan Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$18.37 Mil. Therefore, InnoCan Pharma's EV-to-Revenue for today is 4.60.

The historical rank and industry rank for InnoCan Pharma's EV-to-Revenue or its related term are showing as below:

XCNQ:INNO' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.66   Med: 11.49   Max: 269.68
Current: 4.6

During the past 6 years, the highest EV-to-Revenue of InnoCan Pharma was 269.68. The lowest was 3.66. And the median was 11.49.

XCNQ:INNO's EV-to-Revenue is ranked worse than
73.93% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.38 vs XCNQ:INNO: 4.60

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), InnoCan Pharma's stock price is C$0.32. InnoCan Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.07. Therefore, InnoCan Pharma's PS Ratio for today is 4.51.


InnoCan Pharma EV-to-Revenue Historical Data

The historical data trend for InnoCan Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma EV-to-Revenue Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - 6,014.15 735.46 13.46 4.27

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.46 10.26 6.64 6.10 4.27

Competitive Comparison of InnoCan Pharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's EV-to-Revenue falls into.



InnoCan Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

InnoCan Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=84.543/18.371
=4.60

InnoCan Pharma's current Enterprise Value is C$84.54 Mil.
InnoCan Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$18.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

InnoCan Pharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.32/0.071
=4.51

InnoCan Pharma's share price for today is C$0.32.
InnoCan Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018